What is one absolute contraindication for thrombolytic therapy in cases of myocardial infarction?

Active bleeding represents an absolute contraindication for thrombolytic therapy in cases of myocardial infarction. The administration of thrombolytics aims to dissolve blood clots, but in the presence of active bleeding, this can lead to a significant risk of exacerbating the hemorrhage. Thrombolytics can affect clotting mechanisms in the body, potentially leading to uncontrollable bleeding which could be life-threatening.

In contrast, other conditions like uncontrolled hypertension, recent trauma, and a history of a previous stroke present varying levels of risk but are typically evaluated in the context of the overall clinical picture and are not classified as absolute contraindications. For example, while uncontrolled hypertension can increase the risk of bleeding, it may be managed or documented as a relative contraindication. Similarly, recent trauma or a previous stroke may necessitate careful consideration and further investigation, but they do not universally rule out the possibility of thrombolytic therapy.